title: Effects of the protein tyrosine kinase inhibitor, SU5614, on leukemic and normal stem cells.
abstract: FLT3 activating mutations are the most frequent single genetic abnormality in patients with acute myeloid leukemia. Thus targeting the FLT3 activated kinase is a promising treatment approach. We wanted to test whether the protein tyrosine kinase inhibitor SU5614 selectively eliminates leukemic stem cells while sparing their normal counterparts.
authors.forename: Natalia
authors.initials: N
authors.lastname: Arseni
authors.forename: Farid
authors.initials: F
authors.lastname: Ahmed
authors.forename: Wolfgang
authors.initials: W
authors.lastname: Hiddemann
authors.forename: Christian
authors.initials: C
authors.lastname: Buske
authors.forename: Michaela
authors.initials: M
authors.lastname: Feuring-Buske
mesh_terms: D000328:Adult; D000368:Aged; D002478:Cells, Cultured; D006412:Hematopoietic Stem Cells / Q000187:drug effects* / Q000201:enzymology*; D006801:Humans; D007211:Indoles / Q000494:pharmacology* / Q000627:therapeutic use; D015470:Leukemia, Myeloid, Acute / Q000188:drug therapy / Q000201:enzymology* / Q000235:genetics; D008875:Middle Aged; D047428:Protein Kinase Inhibitors / Q000494:pharmacology / Q000627:therapeutic use; D011505:Protein-Tyrosine Kinases / Q000037:antagonists & inhibitors* / Q000378:metabolism; D051941:fms-Like Tyrosine Kinase 3 / Q000235:genetics
chemical_list: D007211:Indoles; D047428:Protein Kinase Inhibitors; C416849:SU 5614; C497970:FLT3 protein, human; D011505:Protein-Tyrosine Kinases; D051941:fms-Like Tyrosine Kinase 3